Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  blinatumomab
Find trials that include:  Any drugs shown
Results 1-15 of 15 for your search:
Start Over
Expanded Access Protocol of Blinatumomab in Pediatric and Adolescent Subjects With Relapsed and/or Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)
Status: Active
Phase: Phase IV
Type: Treatment
Age: 28 days to 17 years
Trial IDs: 20130320, NCI-2015-00115, NCT02187354
Study to Evaluate Safety and Efficacy of Blinatumomab in Subjects With Relapsed/Refractory (R/R) Aggressive B-Cell NHL
Status: Active
Phase: Phase III, Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 20150292, NCI-2017-00688, 2016-002044-16, NCT02910063
Combination Chemotherapy in Treating Patients with Acute Lymphoblastic Leukemia or Lymphoma
Status: Active
Phase: Phase III, Phase II
Type: Treatment
Age: 1 to 18
Trial IDs: TOT17, NCI-2017-00582, NCT03117751
Combination Chemotherapy with or without Blinatumomab in Treating Patients with Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia
Status: Active
Phase: Phase III
Type: Treatment
Age: 30 to 70
Trial IDs: E1910, NCI-2013-02229, ECOG-E1910, PE1910_A08PAMDREVW01, NCT02003222
Blinatumomab in Treating Younger Patients with Relapsed B-cell Acute Lymphoblastic Leukemia
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 1 to 30
Trial IDs: AALL1331, NCI-2014-00631, COG-AALL1331, NCT02101853
Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients with Acute Lymphoblastic Leukemia
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 65 and over
Trial IDs: S1318, NCI-2014-01047, SWOG-S1318, NCT02143414
Blinatumomab in Treating Patients with B-cell Acute Lymphoblastic Leukemia with Minimal Residual Disease
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 2014-0844, NCI-2015-01547, NCT02458014
Blinatumomab and T Cell Depleted Donor Blood Cell Transplant in Treating Younger Patients with Relapsed or Refractory Hematologic Malignancy after a Previous Transplant
Status: Temporarily closed
Phase: Phase II
Type: Treatment
Age: 21 and under
Trial IDs: REF2HCT, NCI-2016-00812, NCT02790515
Blinatumomab after Donor Stem Cell Transplant in Treating Patients with Acute Lymphoblastic Leukemia
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 to 70
Trial IDs: 2015-0576, NCI-2016-01182, NCT02807883
Blinatumomab in Treating Patients with Relapsed or Refractory Non-Hodgkin Lymphoma
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 16-118, NCI-2016-01369, NCT02811679
Ibrutinib and Blinatumomab in Treating Patients with Relapsed or Refractory B Acute Lymphoblastic Leukemia
Status: Not yet active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: UCDCC#266, NCI-2016-01882, NCT02997761
Blinatumomab and Combination Chemotherapy as Frontline Therapy in Treating Patients with B Acute Lymphoblastic Leukemia
Status: Active
Phase: Phase II
Type: Treatment
Age: 14 and over
Trial IDs: 2014-0845, NCI-2017-00596, NCT02877303
Lenalidomide and Blinatumomab in Treating Patients with Relapsed Non-Hodgkin Lymphoma
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 9924, NCI-2015-01640, PHI-79, NCT02568553
Blinatumomab and Nivolumab with or without Ipilimumab in Treating Patients with Poor-Risk Relapsed or Refractory CD19+ Precursor B-Lymphoblastic Leukemia
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 16 and over
Trial IDs: 10030, NCI-2016-01300, NCT02879695
Blinatumomab after Stem Cell Transplant in Treating Patients with Diffuse Large B-cell Lymphoma or Transformed Large Cell Lymphoma
Status: Not yet active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 201704108, NCI-2017-00731, NCT03072771
Start Over